c-Kit

Imatinib-d8 is a deuterium-labeled derivative of Imatinib, a selective inhibitor targeting c-Kit and other tyrosine kinases, including BCR/ABL, v-Abl, and PDGFR. This compound exhibits potent anti-cancer activity by inhibiting kinase activity, making it a valuable tool for research in oncology and molecular biology. Its deuterium labeling allows for advanced tracking in pharmacokinetic studies and metabolic research.

Velzatinib is a selective inhibitor of c-KIT and targets multiple receptor tyrosine kinases including PDGFRB, PDGFRA, CSF1R, FLT3, and LCK. With IC50 values of 2.6 nM for PDGFRB and 44 nM for c-KIT, it demonstrates potent antitumor activity. Velzatinib has shown efficacy in xenograft mouse models, making it a valuable tool for cancer research and drug development targeting dysregulated growth signaling pathways.

c-Kit Receptor modulator-1 is a selective modulator of the c-Kit receptor, primarily involved in cell signaling pathways associated with hematopoiesis and mast cell function. This compound exhibits potent activity against malignancies such as canine mastocytoma, human gastrointestinal stromal tumors, and small cell lung cancer. It is a valuable tool for research focused on tumor biology and therapeutic interventions targeting c-Kit signaling pathways.

c-Kit-IN-12 is a potent inhibitor of the c-Kit receptor with an IC50 value of less than 10 nM in various KIT mutant cell lines, including BAF3 KIT EX11 DEL, EX11 DEL/D816H, EX11 DEL/T670I, and EX11 DEL/V654A. This compound is valuable for investigating c-Kit-related pathologies, particularly in cancer research. Its specificity and efficacy make it a useful tool for elucidating the role of c-Kit in oncogenic processes and for exploring potential therapeutic strategies.

(S)-c-Kit-IN-12 is a potent c-Kit inhibitor, exhibiting an IC50 value of less than 10 nM across four different KIT mutant cell models, including BAF3 KIT EX11 DEL, EX11 DEL/D816H, EX11 DEL/T670I, and EX11 DEL/V654A. This compound is suitable for investigating c-Kit-related diseases, particularly in cancer research applications, where dysregulation of c-Kit signaling is implicated.

Vimseltinib is a selective dual inhibitor of c-FMS (CSF-IR) and c-Kit, demonstrating IC50 values of less than 0.01 μM and 0.1-1 μM, respectively. This compound exhibits robust biological activity, making it a valuable tool for investigating signaling pathways involved in hematopoiesis and various pathologies such as cancer and inflammatory diseases. The oral bioavailability of Vimseltinib enhances its potential for in vivo studies and therapeutic applications.

Bezuclastinib is a highly selective inhibitor of the c-kit tyrosine kinase, demonstrating potent activity against the KIT D816V mutation. This compound is valuable for researching nonadvanced systemic mastocytosis (NonAdvSM) and provides insight into the underlying mechanisms of this condition. Its oral bioavailability makes it a convenient option for in vivo studies targeting c-kit dysregulation.

Elenestinib is a selective orally active tyrosine kinase inhibitor, demonstrating a potent inhibitory effect on the KIT D816V mutant with an IC50 value of 6 nM. Its mechanism of action is primarily focused on inhibiting aberrant signaling pathways associated with systemic mastocytosis. Due to its limited ability to cross the blood-brain barrier, Elenestinib is particularly applicable in the investigation of hematologic disorders related to mast cell proliferation and activity.

c-Kit-IN-5 is a potent c-Kit inhibitor, demonstrating IC50 values of 22 nM in kinase assays and 16 nM in cellular assays. This compound exhibits over 200-fold selectivity for c-Kit compared to other kinases, such as KDR, p38, Lck, and Src. Due to its favorable pharmacokinetic properties, c-Kit-IN-5 is well-suited for research applications exploring c-Kit-related signaling pathways and their implications in various diseases, including cancer.

Labuxtinib is a potent dual inhibitor of c-Kit and PDGFR, effectively blocking cell proliferation driven by c-Kit or PDGFR signaling pathways. This compound is suitable for research applications targeting mast cell-associated diseases, respiratory conditions, inflammatory disorders, fibrosis, and metabolic diseases. Its dual mechanism of action makes Labuxtinib a valuable tool for investigating the molecular underpinnings of these diseases and potential therapeutic strategies.

Telatinib mesylate is a potent, orally active inhibitor of VEGFR2, VEGFR3, PDGFα, and c-Kit, exhibiting IC50 values of 6 nM, 4 nM, 15 nM, and 1 nM respectively. This compound effectively impedes angiogenesis and tumor cell proliferation, making it a valuable tool in cancer research. Its selective targeting of key signaling pathways has potential applications in studying tumor microenvironments and in developing therapeutic strategies for various malignancies.

Elenestinib phosphate is an orally active tyrosine kinase inhibitor that selectively targets the KIT D816V mutation, exhibiting an IC50 of 0.2 nM. This compound's targeted inhibition is particularly relevant for studying systemic mastocytosis, as it provides insights into the role of mutated KIT in this condition. Notably, elenestinib phosphate has limited capacity to penetrate the blood-brain barrier, making it suitable for investigating its effects in peripheral tissues.

KBP-7018 is a selective tyrosine kinase inhibitor targeting c-KIT, PDGFR, and RET. It demonstrates potent inhibition with IC50 values of 10 nM for c-KIT, 7.6 nM for PDGFR, and 25 nM for RET. This compound is valuable for investigating the molecular mechanisms and potential treatments related to idiopathic pulmonary fibrosis.

c-Kit-IN-7 is a potent c-Kit inhibitor that demonstrates an IC50 of ≤10 nM. It effectively inhibits cell proliferation in GIST430 and BaF3 mutant cell lines, with IC50 values of ≤100 nM. This compound is crucial for research focused on cancers driven by c-KIT kinase mutations, providing valuable insights into therapeutic strategies targeting this pathway.

PLX647 dihydrochloride is a potent and selective dual inhibitor of FMS and KIT kinases, exhibiting IC50 values of 28 nM and 16 nM, respectively. This compound demonstrates high selectivity for FMS and KIT over a broad spectrum of 400 kinases at a concentration of 1 μM, with minimal activity against FLT3 and KDR (IC50s of 91 nM and 130 nM, respectively). PLX647 dihydrochloride is valuable for research applications focused on hematopoietic and oncogenic signaling pathways.

c-Kit-IN-14 is a selective inhibitor of the c-Kit kinase, effectively blocking its phosphorylation with an IC50 of 0.4 nM for pKIT. It demonstrates potent activity against Exon 11 c-Kit mutations, also with an IC50 of 0.4 nM. This compound is primarily utilized in research related to mast cell-mediated disorders, including urticaria, providing insights into therapeutic strategies targeting c-Kit signaling pathways.

c-Kit-IN-13 is a highly selective c-kit kinase inhibitor that effectively blocks the autophosphorylation of wild-type c-kit, demonstrating an IC50 of 0.3 nM for pKIT and 0.9 nM for Exon 11 KIT. This compound is particularly useful in researching mast cell-mediated conditions, including urticaria, providing insights into the role of c-kit in these pathologies. Its potent inhibitory activity makes it a valuable tool for studies focused on targeted therapies in hematological cancers and related disorders.

KBP-7018 hydrochloride is a selective inhibitor of tyrosine kinases, specifically targeting c-KIT, PDGFR, and RET. It exhibits significant inhibitory potency, with IC50 values of 10 nM, 7.6 nM, and 25 nM, respectively. This compound is utilized in research focused on idiopathic pulmonary fibrosis, facilitating investigations into pathways associated with this condition.

APcK110 is a potent inhibitor of the Kit receptor tyrosine kinase, with applications in the study of acute myeloid leukemia (AML). This compound has been shown to induce apoptosis in AML cells, offering valuable insights into therapeutic strategies for targeting this malignancy. Researchers can utilize APcK110 to explore mechanisms of resistance, cell signaling pathways, and potential combination therapies in AML treatment.

KI-328 is a selective inhibitor of the c-Kit kinase, specifically designed to target various mutant forms associated with acute myeloid leukemia (AML). It demonstrates effective inhibition of both wild-type and certain mutant KIT-expressing cell lines, although it shows diminished activity against the D816V-KIT variant. Comparative analyses with other potent KIT inhibitors indicate varying degrees of efficacy across different mutant forms, highlighting the necessity for targeted assessments in clinical applications. KI-328 provides a valuable tool for research focused on the biological mechanisms of KIT mutations and their implications in leukemia therapies.

c-Kit-IN-11 is a selective inhibitor of c-Kit, exhibiting an IC50 of 76 nM in Mo7e cells. This compound is valuable in research related to inflammatory conditions such as asthma, as well as in the study of malignant cancers. Its targeted inhibition of c-Kit makes it a useful tool for investigating the underlying mechanisms of these diseases and potential therapeutic strategies.

GW694590A is an inhibitor targeting firefly luciferase (Fluc) that enhances the stability of the MYC protein, subsequently increasing its endogenous levels. This compound also inhibits receptor tyrosine kinases, demonstrating significant reductions in DDR2, KIT, and PDGFRα activity at 1 μM. GW694590A serves as a versatile protein kinase inhibitor, influencing both ATP-dependent and -independent luciferase systems, making it valuable for studies in cellular signaling and gene expression regulation.

c-Kit-IN-8 is a selective inhibitor of the c-Kit kinase, demonstrating high efficacy with an IC50 greater than 1 μM for uKIT kinase. It effectively reduces the proliferation of cancer cells, including GIST430 and BaF3 cell lines, with an IC50 of over 0.1 μM. This compound is valuable for research in cancer biology, particularly in studies focusing on c-Kit-related signaling pathways and therapeutic resistance in oncogenesis.

c-Kit-IN-10 is a selective inhibitor of the c-Kit receptor tyrosine kinase, which plays a critical role in hematopoiesis, cell signaling, and tumorigenesis. This compound demonstrates potent anti-proliferative activity against c-Kit-dependent cancers and has potential applications in the study of inflammatory conditions such as asthma. Researchers may utilize c-Kit-IN-10 to investigate its therapeutic effect on disease models characterized by aberrant c-Kit signaling.